@article{d24abd2e61224bf0b318b84c1aadca33,
title = "The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper: Critical Reviews in Oncology/Hematology",
abstract = "Background: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease. Methods: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IV aggressive , those with < 5 CTCs as Stage IV indolent. Survival was analyzed using Kaplan-Meier curves and the log rank test. Results: For all patients, Stage IV indolent patients had longer median overall survival than those with Stage IV aggressive (36.3 months vs. 16.0 months, P < 0.0001) and similarly for de novo MBC patients (41.4 months Stage IV indolent vs. 18.7 months Stage IV aggressive , p < 0.0001). Moreover, patients with Stage IV indolent disease had significantly longer overall survival across all disease subtypes compared to the aggressive cohort: hormone receptor-positive (44 months vs. 17.3 months, P < 0.0001), HER2-positive (36.7 months vs. 20.4 months, P < 0.0001), and triple negative (23.8 months vs. 9.0 months, P < 0.0001). Similar results were obtained regardless of prior treatment or disease location. Conclusions: We confirm the identification of two subgroups of MBC, Stage IV indolent and Stage IV aggressive , independent of clinical and molecular variables. Thus, CTC count should be considered an important tool for staging of advanced disease and for disease stratification in prospective clinical trials. {\textcopyright} 2018",
keywords = "Biomarker, Circulating tumor cells, CTCs, MBC, Metastatic breast cancer, Survival, adult, aged, cancer localization, cancer prognosis, cancer staging, cancer survival, cell counting, circulating tumor cell, cohort analysis, controlled study, female, human, human epidermal growth factor receptor 2 positive breast cancer, major clinical study, metastatic breast cancer, outcome assessment, overall survival, retrospective study, Review, survival analysis, triple negative breast cancer, breast tumor, consensus, expert witness, international cooperation, pathology, patient selection, standards, tumor embolism, tumor marker, Biomarkers, Tumor, Breast Neoplasms, Consensus, Expert Testimony, Female, Humans, International Agencies, Neoplasm Staging, Neoplastic Cells, Circulating, Patient Selection",
author = "M. Cristofanilli and J.-Y. Pierga and J. Reuben and A. Rademaker and A.A. Davis and D.J. Peeters and T. Fehm and F. Nol{\'e} and R. Gisbert-Criado and D. Mavroudis and S. Grisanti and M. Giuliano and J.A. Garcia-Saenz and J. Stebbing and C. Caldas and P. Gazzaniga and L. Manso and R. Zamarchi and {de Lascoiti}, A.F. and {De Mattos-Arruda}, L. and M. Ignatiadis and L. Cabel and {van Laere}, S.J. and F. Meier-Stiegen and M.-T. Sandri and J. Vidal-Martinez and E. Politaki and F. Consoli and D. Generali and M.R. Cappelletti and E. Diaz-Rubio and J. Krell and S.-J. Dawson and C. Raimondi and A. Rutten and W. Janni and E. Munzone and V. Cara{\~n}ana and S. Agelaki and C. Almici and L. Dirix and E.-F. Solomayer and L. Zorzino and L. Darrigues and J.S. Reis-Filho and L. Gerratana and S. Michiels and F.-C. Bidard and K. Pantel",
note = "Cited By :18 Export Date: 26 February 2020 CODEN: CCRHE Correspondence Address: Cristofanilli, M.; FACP, Robert H Lurie Comprehensive Cancer Center, Northwestern University, 710 N Fairbanks Court, Suite 8-250A, United States; email: Massimo.Cristofanilli@nm.org Chemicals/CAS: Biomarkers, Tumor References: Baselga, J., Campone, M., Piccart, M., Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer (2012) N. Engl. J. Med., 366, pp. 520-529; Bidard, F.C., Peeters, D.J., Fehm, T., Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data (2014) Lancet Oncol., 15, pp. 406-414; Cristofanilli, M., Budd, G.T., Ellis, M.J., Circulating tumor cells, disease progression, and survival in metastatic breast cancer (2004) N. Engl. J. Med., 351, pp. 781-791; Cristofanilli, M., Hayes, D.F., Budd, G.T., Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer (2005) J. Clin. Oncol., 23, pp. 1420-1430; DeSantis, C.E., Ma, J., Goding Sauer, A., Newman, L.A., Jemal, A., Breast cancer statistics, 2017, racial disparity in mortality by state (2017) CA Cancer J. Clin., 67, pp. 439-448; Duffy, M.J., Harbeck, N., Nap, M., Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM) (2017) Eur. J. Cancer, 75, pp. 284-298; Finn, R.S., Crown, J.P., Lang, I., The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study (2015) Lancet Oncol., 16, pp. 25-35; Finn, R.S., Martin, M., Rugo, H.S., Palbociclib and letrozole in advanced breast cancer (2016) N. Engl. J. Med., 375, pp. 1925-1936; Finn, R.S., Crown, J., Lang, I., Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18) (2017) J. Clin. Oncol., 35. , suppl; abstr 1001; Ghoncheh, M., Pournamdar, Z., Salehiniya, H., Incidence and mortality and epidemiology of breast cancer in the world (2016) Asian Pac. J. Cancer Prev., 17, pp. 43-46; Giuliano, A.E., Connolly, J.L., Edge, S.B., breast cancer-major changes in the american joint committee on cancer eighth edition cancer staging manual (2017) CA Cancer J. Clin., 67, pp. 290-303; Gradishar, W.J., Anderson, B.O., Balassanian, R., Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology (2018) J. Compr. Cancer Netw., 16, pp. 310-320; Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Ribociclib as first-line therapy for HR-Positive, advanced breast cancer (2016) N. Engl. J. Med., 375, pp. 1738-1748; Koren, S., Bentires-Alj, M., Breast tumor heterogeneity: source of fitness, hurdle for therapy (2015) Mol. Cell, 60, pp. 537-546; Meng, S., Tripathy, D., Shete, S., uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues (2006) Proc. Natl. Acad. Sci. U. S. A., 103, pp. 17361-17365; Paolillo, C., Mu, Z., Rossi, G., Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells (2017) Clin. Cancer Res., 23, pp. 6086-6093; Piccart, M., Hortobagyi, G.N., Campone, M., Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 (2014) Ann. Oncol., 25, pp. 2357-2362; Polyak, K., Heterogeneity in breast cancer (2011) J. Clin. Invest., 121, pp. 3786-3788; Powell, A.A., Talasaz, A.H., Zhang, H., Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines (2012) PLoS One, 7; Rossi, G., Mu, Z., Rademaker, A.W., Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer (2018) Clin. Cancer Res., 24, pp. 560-568; Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2018 (2018) CA Cancer J. Clin., (68), pp. 7-30; Sledge, G.W., Jr., Toi, M., Neven, P., MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy (2017) J. Clin. Oncol., 35, pp. 2875-2884; Smerage, J.B., Barlow, W.E., Hortobagyi, G.N., Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500 (2014) J. Clin. Oncol., 32, pp. 3483-3489; Turner, N.C., Ro, J., Andre, F., Palbociclib in Hormone-Receptor-Positive advanced breast cancer (2015) N. Engl. J. Med., 373, pp. 209-219; Van Poznak, C., Somerfield, M.R., Bast, R.C., Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: american society of clinical oncology clinical practice guideline (2015) J. Clin. Oncol., 33, pp. 2695-2704; Weigelt, B., Peterse, J.L., van{\textquoteright} t Veer, L.J., Breast cancer metastasis: markers and models (2005) Nat. Rev. Cancer, 5, pp. 591-602; Yu, M., Bardia, A., Wittner, B.S., Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition (2013) Science, 339, pp. 580-584; Yu, M., Bardia, A., Aceto, N., Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility (2014) Science, 345, pp. 216-220",
year = "2019",
doi = "10.1016/j.critrevonc.2018.12.004",
language = "English",
volume = "134",
pages = "39--45",
journal = "Crit. Rev. Oncol. Hematol.",
issn = "1879-0461",
publisher = "Elsevier Ireland Ltd",
}